SUPN   $32.09  0.79% Market Closed After Close 32.13 0.12%

Supernus Pharmaceuticals Inc
Last Events:

2023-08-09 Trend pattern changed from сужающийся канал to нисходящий клин.

2023-08-09 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it falls. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Trend pattern changed from расходящийся клин с наклоном вниз to сужающийся канал.

2023-08-06 Signal in MACD changed from bearish weakening to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and it crossed the zero line from the bottom. These factors mean that there is probably a growing trend. Last signal: up-crossing the middle level.

2023-08-06 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-05 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in RSI changed from bullish to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.

2023-08-03 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 4
Target Price Mean 39.25
Mean unverified/preliminary 39.25 / 39.25
Target Price Low / High 36.00 / 43.00
Median / STD DEV 39.00 / 2.99
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy None
ma50 None None None
ma100 Buy Buy ActivelyBuy
Candlestick PatternSept. 17, 2024 Bullish Ladder - is a made up of five candlesticks. Pattern appears on a downtrend. Three strong black candlesticks follows by the fourth black candlestick closes also lower but has a long upper shadow. The fifth day is a strong white with an open above the previous day’s body. Considered to be a bullish reversal pattern.
ISIN US8684591089
ceo Mr. Jack A. Khattar M.B.A.
Website https://www.supernus.com
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.